Sino Biopharmaceutical Limited

OTCPK:SBMF.F Stock Report

Market Cap: US$6.9b

Sino Biopharmaceutical Valuation

Is SBMF.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SBMF.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
US$1.21
Fair Value
69.5% undervalued intrinsic discount
23
Number of Analysts

Below Fair Value: SBMF.F ($0.37) is trading below our estimate of fair value ($1.21)

Significantly Below Fair Value: SBMF.F is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SBMF.F?

Key metric: As SBMF.F is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for SBMF.F. This is calculated by dividing SBMF.F's market cap by their current earnings.
What is SBMF.F's PE Ratio?
PE Ratio23.7x
EarningsCN¥2.14b
Market CapCN¥50.66b

Price to Earnings Ratio vs Peers

How does SBMF.F's PE Ratio compare to its peers?

The above table shows the PE ratio for SBMF.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average28.6x
ELAN Elanco Animal Health
27.7x1.6%US$5.7b
JAZZ Jazz Pharmaceuticals
16.1x12.3%US$7.3b
CORT Corcept Therapeutics
50.4x37.1%US$7.1b
PBH Prestige Consumer Healthcare
20.2x4.9%US$4.3b
SBMF.F Sino Biopharmaceutical
23.7x12.6%US$54.0b

Price-To-Earnings vs Peers: SBMF.F is good value based on its Price-To-Earnings Ratio (23.7x) compared to the peer average (28.6x).

Price to Earnings Ratio vs Industry

How does SBMF.F's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

8 CompaniesPrice / EarningsEstimated GrowthMarket Cap
OGN Organon
3x-8.3%US$3.77b
NDOI Endo
0.7xn/aUS$2.18b
PROC.F Procaps Group
2.5xn/aUS$126.36m
KPRX Kiora Pharmaceuticals
1.9x0.2%US$10.80m
SBMF.F 23.7xIndustry Avg. 19.5xNo. of Companies8PE01224364860+
8 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: SBMF.F is expensive based on its Price-To-Earnings Ratio (23.7x) compared to the US Pharmaceuticals industry average (19.5x).

Price to Earnings Ratio vs Fair Ratio

What is SBMF.F's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SBMF.F PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio23.7x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate SBMF.F's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SBMF.F forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
US$0.57
0%
20.3%US$0.88US$0.39n/a23
Feb ’26US$0.37
US$0.58
+55.1%
20.3%US$0.88US$0.39n/a23
Jan ’26n/a
US$0.58
0%
20.4%US$0.88US$0.39n/a22
Dec ’25US$0.42
US$0.57
+37.1%
20.7%US$0.89US$0.37n/a23
Nov ’25n/a
US$0.58
0%
20.6%US$0.90US$0.38n/a23
Oct ’25US$0.47
US$0.60
+28.1%
22.8%US$0.91US$0.40n/a23
Sep ’25n/a
US$0.59
0%
23.1%US$0.90US$0.39n/a23
Aug ’25US$0.36
US$0.59
+62.7%
29.7%US$1.17US$0.38n/a23
Jul ’25US$0.31
US$0.59
+88.5%
29.2%US$1.16US$0.38n/a23
Jun ’25US$0.37
US$0.59
+60.7%
29.4%US$1.17US$0.38n/a23
May ’25n/a
US$0.60
0%
28.9%US$1.17US$0.39n/a22
Apr ’25US$0.35
US$0.60
+72.7%
30.0%US$1.17US$0.39n/a21
Mar ’25n/a
US$0.65
0%
32.1%US$1.18US$0.39n/a21
Feb ’25US$0.33
US$0.65
+94.6%
31.7%US$1.19US$0.39US$0.3722
Jan ’25n/a
US$0.72
0%
43.1%US$1.83US$0.39n/a24
Dec ’24n/a
US$0.71
0%
42.3%US$1.81US$0.38US$0.4225
Nov ’24n/a
US$0.70
0%
42.4%US$1.79US$0.38n/a25
Oct ’24US$0.34
US$0.72
+112.6%
39.4%US$1.79US$0.38US$0.4726
Sep ’24n/a
US$0.74
0%
37.1%US$1.80US$0.38n/a27
Aug ’24US$0.45
US$0.81
+80.9%
37.2%US$1.82US$0.47US$0.3624
Jul ’24US$0.39
US$0.88
+123.9%
35.1%US$1.80US$0.48US$0.3122
Jun ’24n/a
US$0.89
0%
34.2%US$1.78US$0.49US$0.3722
May ’24US$0.51
US$0.91
+78.4%
33.8%US$1.82US$0.51n/a22
Apr ’24n/a
US$0.95
0%
31.9%US$1.84US$0.51US$0.3522
Mar ’24US$0.56
US$0.95
+70.9%
31.4%US$1.82US$0.53n/a22
Feb ’24US$0.62
US$0.98
+57.4%
31.6%US$1.86US$0.54US$0.3322
Analyst Price Target
Consensus Narrative from 23 Analysts
US$0.56
Fair Value
33.6% undervalued intrinsic discount
23
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/10 00:46
End of Day Share Price 2025/02/03 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Sino Biopharmaceutical Limited is covered by 50 analysts. 23 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ling ZhangBNP Paribas Securities (Asia)
Justin LiuBNP Paribas Securities (Asia)
Sharon ShiBOCI Research Ltd.